Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon

MA-204: Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon

This study was design to establish the effectiveness of PillCam® Platform with the PillCam® COLON 2 capsule as demonstrated by the identification of subjects with polyps as compared to optical colonoscopy.

Study Overview

• Status: Completed
• Conditions: CRC Screening
• Intervention / Treatment: Device: PillCam® COLON 2 procedure; Procedure: Colonoscopy

Detailed Description

This multi-center study was designed to evaluate the safety and effectiveness of PillCam Platform with the PillCam COLON 2 capsule as demonstrated by the identification of subjects with polyps, compared to optical colonoscopy.

884 subjects participated in this study. All subjects that were enrolled in this study were indicated and scheduled to undergo colonoscopy based on their age and demographics for screening for polyps.

Each subject was required to follow a bowel preparation regimen and to undergo capsule endoscopy (CE) followed by optical colonoscopy (OC). The optical colonoscopy procedure was scheduled 4-6 weeks after CE procedure to allow for the central readers reading of the PillCam RAPID video.

The colonoscopist was kept blinded to the CE results

• Study Type: Interventional
• Enrollment (Actual): 884
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Israel
  • Beer-Sheva, Israel, 84101
    • Soroka University Medical Center
  • Haifa, Israel, 31096
    • Rambam Medical Center
  • Jerusalem, Israel
    • Bikur Holim Hospital
  • Petach-Tikwa, Israel, 49100
    • Rabin Medical Center
  • Tel Hashomer, Israel
    • The Chaim Sheba Medical Center at Tel-Hashomer
  • Tel-Aviv, Israel, 64239
    • The Tel-Aviv Sourasky Medical Center
• United States
  • Alabama
    • Huntsville, Alabama, United States, 35802
      • Alabama Digestive Disorders Center P.C.
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Indiana University Hospital
  • Kentucky
    • Louisville, Kentucky, United States, 40217
      • Louisville Gastroenterology Associates
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • Specialists in Gastroenterology
  • New York
    • New York, New York, United States, 10075
      • Research Associates of New York
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • UNC Chapel Hill Gastroenterology and Hepatology
  • Ohio
    • Dayton, Ohio, United States, 45440
      • Dayton Gstroenterology Inc.
  • Tennessee
    • Franklin, Tennessee, United States, 37067
      • Franklin Gastroenterology, PLLC
  • Texas
    • Houston, Texas, United States, 77034
      • Gastroenterology Consultants, P.A.
    • Pasadena, Texas, United States, 77505
      • Pasadena Gastroenterology Associates, P.A.
  • Virginia
    • Chesapeake, Virginia, United States, 23320
      • Gastroenterology Associates of Tidewater

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject is between 50 - 75 years of age, and is classified as average risk per the AGA Guidelines on CRC Screening.
2. Subject received an explanation about the nature of the study and agrees to provide written informed consent.

Exclusion Criteria:

1. Subject has a history of colorectal cancer
2. Subjects with history of any positive colon assessment (including CT, optical colonoscopy, sigmoidoscopy etc.)
3. Subject with history of negative colon assessment (including CT, optical colonoscopy, sigmoidoscopy etc.) < 5 years as these subjects would be defined not requiring screening in this time frame
4. Subject has a first degree relative diagnosed with colorectal cancer before the age of 60 years old or 2 (or more) first degree relatives diagnosed with colorectal cancer at any age.
5. Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high risk genetic syndrome.
6. Subject is suspected or diagnosed with inflammatory bowel disease, or chronic ulcerative colitis or Crohn's disease.
7. Subject is suspected or diagnosed with hematochezia, melena, Fe deficiency anemia or any other rectal bleeding, including positive FOBT test of any variety.
8. Subject is suspected or diagnosed with bowel obstruction.
9. Subject has dysphagia or any swallowing disorder.
10. Subject has congestive heart failure.
11. Subject has Type 1 or Type II Diabetes.
12. Subject has had prior abdominal surgery of the gastrointestinal tract in the last 6 months, other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
13. Subject has a cardiac pacemaker or other implanted electro medical device.
14. Subject has any allergy or other known contraindication to the medications used in the study.
15. Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
16. Subject with any condition believed to have an increased risk for capsule retention such as intestinal tumors, radiation enteritis, and incomplete colonoscopies due to obstructions or NSAID enteropathy.
17. Subject with strictures, fistulas and/or chronic constipation.
18. Subject with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters.
19. Subject with known gastrointestinal motility disorders.
20. Subject has known delayed gastric emptying.
21. Subject has any condition, which precludes compliance with study and/or device instructions.
22. Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
23. Subject suffers from life threatening conditions.
24. Concurrent participation in another clinical trial using any investigational drug or device.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sensitivity and Specificity of PillCam Platform With the PillCam COLON 2 Capsule in Detecting Patients With Polyps ≥6 mm Where OC Considered as the Gold Standard Reference	Sensitivity and specificity of PillCam Platform with the PillCam COLON 2 capsule in detecting subjects with polyps equal to or larger than 6 mm. For a given polyp, a match between the PillCam Colon 2 Capsule and optical colonoscopy was considered if the polyp size was assessed within plus or minus 50% of the size of the estimate of the OC measurement and the polyp as appearing within the same colon segment or in adjacent segments. The polyp size measurement by optical colonoscopy was used as the reference standard. Sensitivity measures the proportion of actual positives which are correctly identified as such. Specificity measures the proportion of negatives which are correctly identified as such. positive event defined as patients with polyps ≥6 mm detected by OC procedure.	1 year, same as study duration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sensitivity and Specificity of PillCam Platform With the PillCam COLON 2 Capsule in Detecting Patients With Polyps ≥10 mm Where OC Considered as the Gold Standard Reference	Sensitivity and specificity of PillCam Platform with the PillCam COLON 2 capsule in detecting subjects with polyps equal to or larger than 6 mm. For a given polyp, a match between the PillCam Colon 2 Capsule and optical colonoscopy was considered if the polyp size was assessed within plus or minus 50% of the size of the estimate of the OC measurement and the polyp as appearing within the same colon segment or in adjacent segments. The polyp size measurement by optical colonoscopy was used as the reference standard.	1 year, same as study duration

Collaborators and Investigators

• Sponsor: Medtronic - MITG
• Investigators: Principal Investigator: Douglas Rex, Prof., Indiana University Hospital, Indianapolis, IN, USA

Publications and helpful links

General Publications

• Rex DK, Adler SN, Aisenberg J, Burch WC Jr, Carretero C, Chowers Y, Fein SA, Fern SE, Fernandez-Urien Sainz I, Fich A, Gal E, Horlander JC Sr, Isaacs KL, Kariv R, Lahat A, Leung WK, Malik PR, Morgan D, Papageorgiou N, Romeo DP, Shah SS, Waterman M. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population. Gastroenterology. 2015 May;148(5):948-957.e2. doi: 10.1053/j.gastro.2015.01.025. Epub 2015 Jan 22.

Study record dates

Study Major Dates

• Study Start: June 1, 2011
• Primary Completion (Actual): June 1, 2012
• Study Completion (Actual): June 1, 2012

Study Registration Dates

• First Submitted: June 5, 2011
• First Submitted That Met QC Criteria: June 13, 2011
• First Posted (Estimate): June 14, 2011

Study Record Updates

• Last Update Posted (Actual): August 1, 2019
• Last Update Submitted That Met QC Criteria: July 29, 2019
• Last Verified: July 1, 2012

More Information

Terms related to this study

• Keywords: Colonoscopy; Capsule endoscopy; Polyps
• Other Study ID Numbers: MA-204